Loading...

ELITE PHARMACEUTICALS INC Product Launches 8-K Filing

LT P

ELITE PHARMACEUTICALS INC

()

2025 8-K

Product Launch Announcement

Financial Results Report

Conference Call Announcement

Quarterly Financial Report

Conference Call Update

FDA Approval Granted

Conference Call Announcement

Quarterly Results Update

Financial Statements

Clinical Trials

New Product Launches

Product Shipment

Quarterly Results

External Links:

On November 12, 2025, Elite Pharmaceuticals Inc. announced FDA approval for a generic version of Requip XL® (Ropinirole Extended-Release Tablets) available in multiple strengths (2 mg, 4 mg, 6 mg, 8 mg, and 12 mg), to be marketed under Elite Laboratories, Inc.

AI Assistant

ELITE PHARMACEUTICALS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.